Abstract: β cell replacement with either pancreas or islet transplantation has progressed immensely over the last decades with current 1-and 5-year insulin independence rates of approximately 85% and 50%, respectively. Recent advances are largely attributed to improvements in immunosuppressive regimen, donor selection, and surgical technique. However, both strategies are compromised by a scarce donor source. Xenotransplantation offers a potential solution by providing a theoretically unlimited supply of islets, but clinical application has been limited by concerns for a potent immune response against xenogeneic tissue. β cell clusters derived from embryonic or induced pluripotent stem cells represent another promising unlimited source of insulin producing cells, but clinical application is pending further advances in the function of the β cell like clusters. Exciting developments and rapid progress in all areas of β cell replacement prompted a lively debate by members of the young investigator committee of the International Pancreas
W ithin a century, type 1 diabetes mellitus (T1DM) evolved from fatal diagnosis to a manageable condition with near normal lifespan, complicated by secondary morbidities. [1] [2] [3] [4] The discovery of insulin in the 1920s resulted in reduced mortality before the age of 10 years, plummeting from approximately 85% between 1897 and 1914 and approximately 40% between 1914 and 1922 in the preinsulin era, to less than 10% during 1922 to 1926 and less than 1% in the 1950s. 1, 2 These remarkable results were seen as a cure at the time, 5 so that early experimental attempts to replace pancreatic tissue were abandoned. 6 Decades later, it became apparent that exogenous insulin therapy, although averting death from dehydration, could not prevent hitherto unknown secondary complications, such as diabetic nephropathy, retinopathy, and neuropathy. 7 This recognition rekindled interest in β cell replacement therapy as a truly curative approach, resulting in the first pancreas transplant in 1966 8 and the development of protocols for islet isolation. [9] [10] [11] Although pancreas transplantation was rapidly adapted into clinical practice, 12 the first clinical islet transplant was performed in 1977 13, 14 but unsatisfactory results prevented widespread use. The International Pancreas and Islet Transplantation Association (IPITA) held its first meeting in 1988 and has since pursued the goal to provide a scientific forum for the transplantation of insulin producing tissue in the treatment and cure of diabetes mellitus. 15 In addition, the early 1990s saw the release of 2 milestone trials of large cohorts of people with T1DM (Diabetes Control and Complications Trial [DCCT] ) and type 2 diabetes mellitus (T2DM) (UK Prospective Diabetes Study [UKPDS] ) demonstrating that intensified metabolic control is able to reduce or prevent the development and progression of long-term complications. [16] [17] [18] [19] Intensification of insulin therapy, however, is limited by the inherent risk of hypoglycemia. [20] [21] [22] Hence, efforts to broaden the application of islet and pancreas transplantation increased to resolve this conundrum. In the year 2000, the Edmonton group reported a revised protocol for islet transplantation achieving sustainable islet graft function in a series of nonuremic patients with T1DM, 23 ,24 which triggered a worldwide surge in islet transplantation. Incremental improvements since then enabled outcomes like those seen with pancreas transplants. [25] [26] [27] [28] [29] Unfortunately, both pancreas and islet transplantation are severely compromised by a limited source of donor tissue and the requirement for immunosuppression. Significant strides in xenotransplantation of porcine islets address the limited donor pool but are compromised by a rigorous immune response. β cells derived from embryonic or induced pluripotent stem cells (iPSC) are getting closer to clinical translation, but the uncertain functional capacity of these cells and risk of neoplastic transformation will need to be resolved (Table 1) . Exciting developments and rapid progress in all areas of β cell replacement prompted a lively debate by members of the Young Investigator Committee of IPITA at the 15th World Congress held in Melbourne, Australia, and at the 26th International Congress of The Transplantation Society in Hong Kong. This international group and conference attendees pondered which modality of β cell replacement is likely to predominate the landscape in 10 years, and this debate is revisited and explored further in this review.
Pancreas Transplantation
Since the first pancreas transplant was performed at the University of Minnesota in 1966, more than 50 000 pancreata have been transplanted worldwide. 12 Over this period, pancreas transplantation has evolved from an experimental procedure to become a routine transplant in the modern era. Multiple advances in surgical technique, immunosuppression, and donor/recipient selection now achieve a high rate of success. 12, 52 The traditional indications for a pancreas transplant include T1DM with renal failure and nonuremic T1DM with significant hypoglycemic unawareness. 119 The former is the most common scenario, with 76% of pancreata transplanted as a simultaneous pancreas and kidney (SPK), whereas the remainder are transplanted as a solitary pancreas transplanteither after a kidney (PAK) (11%) or alone (PA) (13%). 12, 91 Five-and 10-year pancreas graft survival rates are 73% and 56% for SPK, 64% and 38% for PAK; and 53 and 36% for PA with outcomes continuing to improve. 92 Given the improving outcomes and the significant benefits for mortality, quality of life, and end-organ complications, indications for pancreas transplantation are expanding to include people with T2DM and older recipients (age ≥ 60 years).
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T2DM comprises the largest of these expanding indications and is increasing, now accounting for 9% of all SPK recipients with excellent results. [120] [121] [122] This is relevant when considering an expanding elderly population and a projected 552 million people with T2DM by 2030. 123 Because of the rapidly increasing numbers of uremic T2DM patients, the United Network of Organ Sharing restricts the number of T2DM patients that can receive SPK transplants to those patients with a C peptide less than 2 ng/mL and a body mass index (BMI) of 30 kg/m 2 or less. This BMI cutoff is likely to increase in the future given that numbers of uremic T2DM patients on the waitlist remain low (United Network of Organ Sharing will continue increasing the BMI cutoff every 6 months by 2 kg/m 2 until 10% of the waitlist is comprised of people with T2DM). It will be critically important to understand the effect of increasing BMI on outcomes in these T2DM patients. The C peptide cutoff is another source of debate, since it does not fully correlate with diabetes type, 124, 125 and C peptide levels do not predict outcome, 126, 127 prompting some to propose raising the cutoff to 10 ng/mL to include more T2DM patients. 120 Risks specific to solid organ pancreas transplantation include those associated with major surgery, increased perioperative cardiovascular risk and high-intensity immunosuppression, which can be minimized with appropriate patient selection and surgical technique. 52 Technical graft loss occurs approximately 5 to 10% of the time. 91, 110 Overall, pancreas transplantation is currently the most effective method of achieving euglycemia in appropriately selected diabetic patients. 25 Advantages of solid organ pancreas transplantation have been clearly demonstrated with respect to patient survival and reduction of diabetic complications. Indeed, pancreas transplantation reduces the risk of cardiovascular events and reverses nephropathy and neuropathy. [100] [101] [102] [103] Pancreas transplantation in the United States has declined despite these excellent results. 91, 122 The reasons for this decline in the United States are not completely understood, but decreased donor organ quality is likely a major factor. For instance, in the United States, only approximately 15% of donated pancreata from deceased donors in 2013 were accepted for transplantation. 128 This is not a surprising trend, given that the donor population is becoming increasingly aged, obese, and diabetic, all factors that adversely affect functional pancreatic graft outcomes. 129 To increase the availability of pancreas organs for transplant, some centers have successfully transplanted pancreata from marginal donors, including donation after circulatory death. [30] [31] [32] [33] [34] Circulatory death donors have yielded excellent outcomes but are currently limited to only 3% of pancreas donors with current acceptance criteria limited to Maastricht Class III and IV (controlled) donors younger than 50 years, BMI less than 30, and warm ischemia time less than 30 minutes. [33] [34] [35] [36] 130 Furthermore, machine perfusion is being tested for hypothermic and normothermic preservations as well as for organ reconditioning to improve the quality of marginal organs. 53 The use of living pancreas donors is a new field of study; currently, 160 transplants using pancreas tissue from living donors have been performed in highly specialized centers with excellent success rates for the recipient and minimal adverse postsurgical events for the donors. 54, 131 However, up to a quarter of living pancreas donors developed diabetes in the long run. 132 Overall, foreseeable efforts to increase the donor pool are unlikely to meet the demand of all patients with T1DM but may help to serve the population of patients with end-stage renal disease or severe hypoglycemic episodes. Surgical technique is constantly evolving, as exemplified by the introduction of duodenoduodenostomy that facilitates graft monitoring and timely antirejection therapy 133, 134 and the use of robotic assistance to perform vascular and enteric anastomosis which could further decrease surgical morbidity. 135 In conclusion, pancreas transplantation is the current criterion standard for β cell replacement therapy in the properly selected diabetic patient and will likely continue to perform well in the next 10 years. In this timeframe, room for improvements lies in expanding donor utilization and quality, expanding recipient selection, a more systematic use of pancreatic biopsies, and improving immunosuppression strategies. 136 In the next few decades, it is likely that pancreas transplantation will continue to develop and be considered as the standard that newer β cell replacement therapies will be measured against.
Islet Transplantation
Clinical islet transplantation demonstrates that long-term insulin independence is achievable, with registry data reporting 47% insulin independence at 3 years. 26, 28, 93, 94, [137] [138] [139] Since the introduction of the Edmonton protocol, 140 immunosuppressive regimens have continued to be modified and improved. One significant advance being the introduction of potent induction therapy in addition to anticytokine management pretransplant, leading to 5-year insulin independence rates of 50% 94 and exceeding 50% in the 2014 Collaborative Islet Transplant Registry report.
26, 93 These improved outcomes place islet transplantation on par with pancreas transplantation. 12, 92, 141 Importantly, the islet transplant procedure has proven to be safe and able to effectively correct hypoglycemia unawareness, reduce severe hypoglycemic episodes, and substantially improve quality of life even when complete exogenous insulin independence is not achieved.
25,27,104-106 Therefore, islet transplantation has made the transition from an experimental, rarely successful therapy to a routine clinical procedure with predictable efficacy. Thus, islet transplantation has gained the status as standard of care for a selected population with T1DM in many countries. In the United States, this status shift is pending the implementation of a recently completed multicenter phase 3 trial into Food and Drug Administration approval of Biological Licensure. 95 Up to now, the widespread use of islet transplantation has been limited by the low efficiency in harvesting enough islet equivalents from a single donor to achieve insulin independence or optimal primary graft function. 55, 142 The less invasive nature of the islet transplant procedure compared with solid organ pancreas transplantation favors recipients at cardiovascular risk with the potential for reversal of secondary complications. In autoislet transplantation, the reintroduction of a patient's own isolated islets has successfully been used to prevent surgically induced diabetes in patients undergoing pancreatic surgery for nonmalignant and malignant diseases. [143] [144] [145] [146] [147] [148] Due to steady improvements in all aspects of the islet isolation process, such as donor selection, pancreas preservation, tissue digestion and purification, and islet culture conditions, higher yields of good quality islets are now routinely achieved in specialized centers worldwide. [26] [27] [28] 96, 104, [149] [150] [151] The US Consortium for Islet Transplantation has developed a unified protocol to standardize the manufacturing process. 56 Exciting new technologies to further automate the isolation process into a closed circuit, with automated renewal of culture media are currently under investigation, which could reduce cost and processing time and increase the quality of isolated islets for autologous or allogeneic islet transplantation. 152 Research into alternative transplant sites is crucial as significant islet graft loss (mainly due to activation of the instant bloodmediated inflammatory reaction [IBMIR] ) and suboptimal engraftment remain as limitations to both autoislet and alloislet transplantation with intrahepatic infusion. [153] [154] [155] In addition, islet infusion into the liver restricts the transplantable tissue volume because increased tissue volume is associated with portal hypertension and acute thrombosis. 156, 157 Outcomes from completed and ongoing clinical trials using the omentum (ClinicalTrials. gov id NCT02213003, NCT02803905), subcutaneous tissue (NCT01652911), gastric submucosa (NCT02402439), intramuscular (NCT02872571, NCT01967186), bone marrow, 158 anterior chamber of the eye (NCT02916680, NCT02846571), or encapsulation devices (NCT02064309) may yield new insights for defining extrahepatic sites for Islet transplantation. Therapeutic intervention for intrahepatic grafts or extrahepatic sites may avoid the early graft loss due to IBMIR and improve engraftment, potentially decreasing the donor to recipient ratio and increasing graft longevity. 155, 159 However, more (pre) clinical studies are needed to establish an alternative site for clinical transplantation applicable to not only allogeneic and xenogeneic donor-derived islets but also to alternative β cell sources, such as pluripotent stem cells (PSC)-derived β cells or bioengineered cells.
The donor pool for both pancreas and islet transplantation is steadily changing worldwide, becoming older and more commonly impacted by metabolic disease, 160 both of which will jeopardize the functional success achieved from a single islet infusion. Understanding the molecular ultrastructure of the pancreas and the impact of such donor variables on it may enable the development of tailored isolation strategies for each different donor type, resulting in improved isolation outcomes from the full range of donors available.
39,161,162
The need for lifelong treatment with immunosuppression, in combination with a limited source of available donor organs, are today the most significant obstacles preventing the wider application of allogeneic islet transplantation, including the treatment of children newly diagnosed with T1DM. 163 However, autologous islet transplant recipients exhibit a slow loss of insulin independence despite absence of allogeneic and autoimmunity [164] [165] [166] revealing a significant contribution of nonimmune factors in long-term graft dysfunction that must be identified and controlled. To combine other cellular therapies with islet transplantation, such as the use of autologous or allogeneic mesenchymal stem cells or regulatory T (Treg) cells, are innovative strategies that could support islet health, revascularization, and induce immune tolerance. 167, 168 Close collaborations with the sharing of findings and increased participation in registries are warranted to improve standard clinical practice and obtain proper reimbursement from health authorities worldwide.
In summary, the experience with pancreas and islet transplantation is an important proof of principle that β cell replacement is capable of restoring normal glucose metabolism, preventing cardiovascular disease, preserving kidney function, and reversing neuropathy. 100, 102, 103, 119 Importantly, islet transplantation has been shown to provide superior glycemic control with less hypoglycemia compared with continuous insulin infusion or multiple daily injections of insulin. 97 Therefore, β cell replacement offers better medical and quality of life outcomes for the individual with comparable or reduced healthcare utilization and cost, compared with exogenous insulin therapy. 27,169-171 However, the cost and risk of the required immunosuppression maintain conventional insulin therapy as favourable for most patients. Finally, the demand for β cell replacement therapy by 422 million people with diabetes worldwide (approximately 40 million people with T1DM), [172] [173] [174] [175] a number that is expected to increase in upcoming decades, [175] [176] [177] emphasizes the urgent need for an alternative β cell source. Currently, xenogeneic, porcine islets, and PSC-derived β cells are racing to fill the gap, and other innovative approaches, such as bioengineered glucose responsive cells and organs grown in chimeric animals, have recently emerged.
Xenoislet Transplantation
Porcine islet transplantation has similarity to allogeneic islet transplantation and therefore may benefit from the decades of experience accumulated in the allogeneic islet transplantation field. Porcine islets were first shown to produce C peptide and survive in humans under standard immunosuppression in 1994 178 ; and in 2006 to have the capacity to restore euglycemia in nonhuman primates (NHPs) when used with experimental, potent immunosuppression. 179, 180 Current studies in porcine-islet xenotransplantation are focused on improving islet functionality and survival in NHPs with the use of less potent immunosuppressive regimens through the utilization of new technologies, including genetic engineering, cellular therapy, and encapsulating devices. These approaches have been applied in preclinical NHP models of porcine islet transplantation (cell therapy, 181 genetic engineering, [61] [62] [63] encapsulation devices [182] [183] [184] [185] [186] ) with islet survival rates approaching or surpassing 1 year.
But why use porcine islets? The short gestation and rapid growth rate of pigs would facilitate a supply of islets adjusted to demand under controlled conditions. 49,50 The use of pigs as a source of tissue would raise little ethical concerns as pigs are already used for human consumption and medicinal products such as insulin, heparin, heart valves and decellularized intestinal submucosa. [187] [188] [189] [190] With a single amino acid difference, porcine insulin binds human receptors and is secreted in a biphasic manner in response to blood glucose, 50, [191] [192] [193] maintaining a fasting blood glucose level similar to humans. 192 Despite these similarities, relevant interspecies differences do exist. For example, manufactured porcine, human, and macaque islets exhibit distinct metabolic profiles exemplified by varied glucose stimulation indices of 1.5, 3.8, and 7.7, respectively. 192 This may indicate that more porcine islet equivalents may be required to reach euglycemia in humans or NHPs, relative to allogeneic islet transplantation. 192 These differences also provide advantages, for example, the reduced metabolic demand of porcine islets compared with human islets may mean that pig islets could better tolerate encapsulation strategies that suffer from limitations of hypoxia. [194] [195] [196] This is a significant consideration because the protection of porcine islets requires aggressive immunosuppression, islet encapsulation provides an avenue to drastically reduce or obliviate the need for Immunosuppression. Encapsulation strategies have been shown to extend the survival of porcine islet grafts from between approximately 1 and 4 weeks to greater than 6 months, and up to 803 days without immunosuppression in NHPs [182] [183] [184] [185] [186] and up to 16 weeks in autoimmune nonobese diabetic mice. 185 However, the metabolic function of encapsulated porcine islets was insufficient in NHP models and in a clinical trial. 194, 197, 198 Approaches, such as encapsulation, are critical for the future success of porcine islet transplantation, because they are subject to vigorous cellular and humoral rejection. [199] [200] [201] [202] [203] For instance, the IBMIR response is a formidable barrier in the xenogeneic setting due to the high level of endogenous preformed circulating antibodies that recognize carbohydrate antigen on porcine cells, which are absent in humans. A prominent example, antigalactose-α1,3-galactose (α-Gal) antibodies, represent up to 1% of the immunoglobulin repertoire in humans, 204, 205 triggering an immediate, potent activation of complement and thrombosis upon exposure to α-Gal. [206] [207] [208] Nevertheless, the genetic modification of porcine islets successfully mitigates IBMIR in NHPs. In a significant advance, the α1,3-galactosyltransferase gene was successfully targeted (GalTKO) to remove the α-Gal xenoepitope, 64, 65 which improved islet engraftment and function. 66 Genetic overexpression of human (h) complement-inhibitory factor CD46 was found to prolong the survival of porcine islets in immunosuppressed diabetic NHPs from 46 days to up to 1 year posttransplantation. This protective effect was mediated by the mitigation of humoral rejection with no detectable reduction in IBMIR-mediated early islet destruction. 61 In contrast, IBMIR and early thrombosis were dramatically suppressed when GalTKO porcine islets transgenic for the complement regulatory factors CD55 + , CD59
+ were transplanted intraportally into diabetic, immunosuppressed baboons. 63 Studies are now underway to generate additional multitransgenic and knock out (KO) pigs to provide further protective benefits to islets when transplanted. 62, [209] [210] [211] For example, it is recognized that other nongalactose xenoreactive human natural antibodies react with transplanted porcine islets. [212] [213] [214] [215] The generation of extensive multi-KO and transgenic pigs to remove all identified detrimental antigens from the xenoislet repertoire and express protective genes represents 1 option. Yet, creating a multi-KO pig for all possible xenoantigens that exists 212 represents a dauntingly long and expensive process with the use of conventional technology. 67 The emergence of endonuclease-gene editing technology (particularly the CRISPR/Cas9 system 67 ) has greatly facilitated high throughput generation of multi-KO pig lines. 67, [216] [217] [218] Indeed, zinc finger endonuclease was used for the rapid generation (7 months) of a pig line with 2 xenoepitopes knocked out, α-Gal and N-Glycolylneuraminic acid. 219 Cells from these double KO pigs have been shown to exhibit reduced human antibody binding and cytotoxicity. 220, 221 Moreover, the power of cas9 genetic modification with somatic cell nuclear transfer has been demonstrated by developing pigs lacking GGTA1/CMAH/β4GalNT2, GGTA1/ CMAH, GGTA1/SLA class I or GGTA1 genes. Of which, GGTA1/CMAH/β4GalNT2 KO porcine cells exhibited significantly reduced human antibody binding to near background levels. 222 These studies illustrate the potential of leveraging gene editing to develop a clinically acceptable IBMIR and xenoreactivity evading donor pig for xenoislet transplantation.
Nonetheless, current genetically modified or encapsulated islets are eventually rejected, [61] [62] [63] [182] [183] [184] [185] [186] highlighting that porcine β cell replacement therapy will require alternate strategies to combat cellular rejection and promote graft tolerance. Interestingly, CD4 + T cells are necessary and sufficient for islet xenograft rejection, 202, [223] [224] [225] underscored by the success of anti-CD154 that significantly extends xenogeneic-islet survival in NHPs when added to a conventional immunosuppressive protocol. 179, 226 However, the use of anti-CD154 results in severe thrombotic complications when used in humans. 227 Strategies that aim to induce xenogeneic-graft tolerance and control the CD4 response include (1) the reengineering of anti-CD154 antibodies, or development of new drugs targeting this pathway 228, 229 while avoiding thrombotic complications but maintaining their capacity to decrease cytotoxic T-cell activation and induce antigen specific Treg cells, [230] [231] [232] (2) the induction of central tolerance by thymic xenografting or mixed chimerism, or (3) the establishment of peripheral tolerance via the in vivo or ex vivo expansion of antigen-specific Treg cells. Seminal studies have found that the use of xenoislets is compatible with tolerizing modalities, 233 such as mixed chimerism [234] [235] [236] [237] or the in vivo or ex vivo expansion and delivery of antigen-specific Treg cells, as human Treg cells operate in the xenogenic setting. [237] [238] [239] The transmission of porcine endogenous retroviruses (PERV) has been a major safety concern, although thus far, no transmission has been observed in human or NHP recipients. 114, [240] [241] [242] Nonetheless, the potential risk is taken extremely seriously with several pretransplant and posttransplant screening processes designed to eliminate endogenous retrovirus, 115, [242] [243] [244] [245] as well as microbial infectious risk. 115, 116 Prescreening of donor herds and postscreening of recipients are 2 obligate processes for all future xenotransplantation trials as outlined by the International Xenotransplantation Association. 51, 117, 118 The generation of transgenic pigs expressing endogenous retrovirus small interfering RNAs has been a strategy to remove the potential PERV risk. 246, 247 However, advances in genome editing have now made it possible to inactivate all 62 copies of PERV in a porcine cell line. 211 Lastly, subcutaneous macroencapsulation will allow the "packaging" of xenogeneic-islets into devices that can be easily and safely retrieved if necessary. The provision of a replenishable O 2 supply may facilitate this approach by addressing the issues of hypoxia and nutrient starvation. 196, 248 Together, these data highlight the utility of porcine xenogeneic islet transplantation for the treatment of T1DM. Indeed, we believe that a future successful xenogeneic-islet regimen will include (1) an encapsulation strategy with local O 2 delivery to avoid direct immune-contact of porcine islets, prevent hypoxia and allow their safe retrieval if necessary; (2) the generation of a multi-KO and multi-KI source pig, accelerated by endonuclease technology. Molecules chosen for KO or KI will be those that address islet loss mediated by IBMIR, humoral and cellular rejection, and (3) a tolerizing therapy aimed at generating antigen-specific Treg cells, which may be combined with a central tolerance inducing regimen to provide long-lasting durable tolerance. 249 Lastly, the use of reengineered anti-CD154 monoclonal antibodies represents a promising adjunct therapy for the induction of xenoislet tolerance. 179, 180, 226, 231 Additional questions to be answered during the next 10 years relate to practicalities of translating xenoislet transplantation, which will be critical for its success. These include decisions to be made by the xeno community, such as the optimal donor line to use and its genetic background, donor age, and standardized preparation of pig islets. 58, 99, 250 These issues have recently been critically reviewed. 251 The consensus statement made by International Xenotransplantation Association provides a framework for conducting clinical trials. 58 Together, these advances in technology and policy place islet xenotransplantation in a strong position to be the β cell replacement therapy of the future.
Pluripotent Stem Cell-Derived b Cells
Deriving functional β cells from PSC 43,44,252 may address most limitations of human and animal donor-derived β cell replacement, including donor shortage, costly, and labor intensive organ procurement and islet isolation procedures and the requirement for immunosuppression. PSC can be cryopreserved and are therefore available off the shelf for directed differentiation into β-like cells.
44-46 Isolated human islets have been successfully cryopreserved for research but not for clinical use. 253 Embryonic stem cell (ESC) generation is restricted to donated, in vitro fertilized ova, giving rise to a cell line that can be propagated indefinitely to provide sufficient cells for virtually all medical applications. However, owing to their allogeneic nature, these cells will necessitate protection from immune attack and their embryonic nature poses ethical concerns. 254 The discovery that somatic cells can be reprogrammed to pluripotency (iPSC) has revolutionized the field because it promises to circumvent both the use of embryonic cells and allogeneic rejection. 255 Previously, the only autologous source of PSC was the costly, prospective banking of umbilical cord blood. Deriving β-like cells for transplant from patient-derived, autologous iPSC presents a nearly ideal source for β cell replacement therapy. The cost and regulatory burden of individual production of autologous iPSC-derived β cells are considered significant barriers to their clinical translation, yet this approach promises immense biological advantages.
The minimal and optimal functional criteria for a β cell replacement product are not clearly defined. 256, 257 Adult islet grafts are stripped of their normal vascularization and innervation, yet retain the complex architecture of islet miniorgans and seem to become revascularized [258] [259] [260] [261] [262] [263] and reinnervated in the liver. 264, 265 It is unknown whether a PSC-derived β cell graft can function similarly to an islet graft. The finetuned insulin secretion of an intrahepatic islet graft reduces glycemic variability and mostly eliminates hypoglycemia. [266] [267] [268] Metabolic studies of islet and pancreas transplant recipients demonstrated that the secretory capacity of islet grafts is typically 25% to 40%, [269] [270] [271] whereas pancreas grafts restore 60% to 100% 272, 273 of the normal insulin secretory capacity in healthy controls. In preclinical and recent onset T1DM, secretory capacity was found to be 25% of normal. 274, 275 Patients with good engraftment and secretory capacity of 40% or greater exhibit less metabolic exhaustion [276] [277] [278] and no functional attrition for the first year posttransplant. 271 This indicates that a larger β cell mass improves long-term graft survival by reducing metabolic stress on the islet or β cell graft. 271, 278, 279 A PSC-derived β cell graft can be scaled to fully restore health secretory capacity and thereby may not be subject to the graft attrition over time observed in islet transplantation.
It remains to be seen whether a graft consisting primarily of single β cells (donor or PSC-derived) will replicate the intricate functional capacity of the endogenous islet miniorgan or pancreas and islet grafts. 256, 257, 280 45 but a demonstration in large animals or humans is lacking. When evaluating the success of PSC derived β-like cell implants in rodent models, contributions of insulin-dependent and independent pathways for glucose normalization must be accounted for via the simultaneous measurement of insulin and C-peptide levels. [290] [291] [292] [293] More informative metabolic measurements, such as clamp studies, CGM, and HbA1c, are challenging to do in mice, limiting the availability of data to predict clinical outcomes. 293 Therefore, primate studies and clinical trials of nonencapsulated PSC-derived β-like cell clusters are urgently needed. A clinical trial currently in the planning phase may address this question. The Boston Autologous Islet Replacement Program 98 aims to differentiate autologous iPSC to β-like cells for autologous transplantation in patients with clinical diabetes due to a nonautoimmune loss of endogenous β cell mass (ie, postpancreatectomy for chronic pancreatitis).
Meanwhile, a first in human, phase I/II trial is currently being conducted by Viacyte Inc. (clinical trials identifier: NCT02239354), in which human ESCs are implanted at the early differentiation stage of endocrine progenitors. 43, 294 To mitigate the risk of tumor formation and to shield the cells from alloimmune and autoimmune attack, progenitor cells are encased in a macroencapsulation device 43,47 placed subcutaneously. It has been shown in mice that these progenitor cells functionally mature after transplantation inside these devices. 47, 294, 295 However, the encapsulation device acts as a diffusion barrier, preventing real-time glucose sensing and insulin secretion that is crucial to islet function. 256, [290] [291] [292] Thus, satisfactory metabolic function has not been demonstrated convincingly with encapsulated islets in primates or humans. 183, 194, 296, 297 Viacyte recently obtained Investigational New Drug approval for a next-generation product, PEC-Direct, permitting vascularization of the encapsulated ESC-derived graft. 298 This approach would remove the diffusion barrier, likely to improve metabolic outcomes, while allowing to contain potential neoplasms and to retrieve the graft if necessary. This strategy will require chronic immunosuppression to protect the allogeneic hESC graft from the immune attack that is not blocked by the encapsulation device, limiting its use to the same high-risk patient population eligible for islet and pancreas transplants.
A less fibrogenic biomaterial, identified in a large screen, 299 has recently been used to microencapsulate hESC-derived β-like cells. 45, 289 The relatively large size of these capsules (1500 μm) further reduced fibrosis, 289, 300 but also increases the diffusion barrier. Nonetheless, a proportion of human cells transplanted into mice were found to survive for 6 months after intraperitoneal transplantation, providing moderate control of fasting blood glucose.
Autologous iPSCs are not expected to elicit an alloimmune response. Although an initial murine study has called this principle into question, 78 several follow-up studies suggest that differentiated progeny of autologous iPS is not rejected. 79, 80 Furthermore, a careful analysis of the immune response to autologous iPSC-derived endothelial cells identified a tolerant signature. 81 In synthesis with studies in clinically relevant NHP models [301] [302] [303] and in humanized mice, 82 these results point toward a more nuanced picture of iPSC immunogenicity which is dependent on the differentiation stage, 79, 81 reprogramming vectors, 79, 81 and the type of differentiated cell. 82, 83 In the first in human trial, using a sheet of autologous iPS-derived retinal pigment epithelial cells for transplantation, no immune rejection was observed. 84 The immunogenicity of specific autologous iPS cell products may need to be assessed in (pre)clinical trials to arrive at a nonimmunogenic cell product. 83 A barrier common to all modes of β cell replacement in patients with T1DM is that cells may be subject to recurrent autoimmune attack. [68] [69] [70] The extent to which β cells for replacement resemble the endogenous β cells may render them increasingly susceptible. Therefore, a balance of a phenotype that permits mature metabolic function but eludes autoimmune attack could be critical for success. 71, 162, 256, 257 Engineering non-β cells to produce and release insulin 71 and immunomodulation 72, 304 are promising approaches to circumvent or regulate recurrent autoimmunity.
Finally, there are well-founded concerns about the potential neoplastic transformation of contaminating PSCs and their progeny. Hence, initial clinical trials of stem cellderived β cells will require a transplant site that allows safe graft retrieval, such as a semipermeable membrane placed in a easily retrievable site (eg, subcutaneous). Ultimately, the safety of PSC-derived β cells may be enhanced by the use of a retrievable transplant site [305] [306] [307] [308] [309] and a stringent manufacturing process excluding remaining pluripotent cells. 60, 310 Encouragingly, several clinical trials using ESC for a variety of diseases are ongoing, and no resulting malignancies have been observed to date. 311 
Emerging b Cell Replacement Strategies
As existing technologies evolve and new discoveries are made, some β cell replacement strategies that presently appear out of reach may become feasible. Here, we mention some nascent developments that may reshape our view of β cell replacement in the upcoming decade.
Alternative generation of endocrine pancreatic cells and tissue include regeneration of endogenous β cells, organ bioengineering, synthetic β cells and growing a human pancreas in animals. Numerous potential pharmacologic agents that can induce regeneration of endogenous β cells in mice have been identified but failed to translate to human β cells. [312] [313] [314] It has also been shown that other pancreatic cell types can transdifferentiate to β cells, including α cells 315 and pancreatic exocrine cells. 316 Recently, a screening approach has identified an Food and Drug Administration-approved drug, Artemisinis, that indirectly targets γ-aminobutyric acid (GABA) receptors, to foster α-to β cell transdifferentiation. 317 Both Artemisinis and GABA potently induced neogenesis of β-like cells from ductal epithelium via an intermediate α cell state in human islets, suggesting that this treatment may be translatable. 318 Reprogramming of exocrine, 316 gastral 319 and hepatic cells are other potential β cell sources. Any of these cells may be subject to autoimmune recurrence.
The main goal of β cell replacement can be distilled to realtime sensing of glucose levels and other relevant parameters, coupled to regulated insulin secretion with swift physiologic kinetics. 256, [320] [321] [322] Several approaches have been undertaken to generate surrogate β cells that harbor some of the intricate physiology of human β cells, from simple ectopic expression of the insulin gene 323 to harnessing the regulated secretory capacity of non-β secretory cells. 324 More recently, HEK293 (human embryonic kidney) cells were transfected with 2 transgenes to enable glucose sensing and insulin release. 71 Rational testing and design resulted in an optimized HEK-β cell constitutively expressing a voltage controlled calcium channel and conditional nuclear factor of activated T-cell (NFAT)-mediated insulin secretion, enabling glucose stimulated insulin secretion in vitro. The glucagon-like peptide 1 (GLP-1) receptor, as well as glucose-dependent expression of GLP-1, was added to increase sensitivity to food intake in vivo. Transplantation of HEK-β cells into diabetic mice improved fasted blood glucose levels and oral GTT. However, glucose metabolism was not normalized, likely due to the time delay imposed by the transcriptional regulation of insulin secretion 320 and compounded by the diffusion barrier imposed by encapsulation and insufficient insulin storage. 71, 325 Importantly, a synthetic non-β cell product may evade recognition by autoimmune memory. Synthetic cell design has also been used for the temporal control of cues for directed differentiation 326 and to improve insulin sensitivity in T2DM. 327 The concept of blastocyst complementation for the generation of a human pancreas organ in a large animal model has recently cleared several technical hurdles. The aim is to generate a pancreas derived entirely from donor cells by injecting donor PSC into the blastocyst of a host that lacks the ability to generate pancreatic tissue. To this end, an apancreatic pig was generated by disruption of the Pdx-1 gene. Blastocyst complementation with wild-type porcine PSC restored normal pancreas organogenesis. 37 The same group successfully generated an interspecies mouse pancreas in rats. Transplantation of isolated interspecies islets reversed hyperglycemia in mice under minor immunosuppression.
38 Evolutionary distance between species precludes the formation of rat-pig chimeras, but a human-pig chimera has recently been generated successfully using human iPSC and wildtype porcine blastocysts. 328 A serious concern is that human PSC could give rise to chimeric brain or germ cells. However, it has been shown that the forced expression of genes preventing mesodermal and ectodermal fate decisions can direct complementary human cells exclusively to endodermal fate. 329 Another elegant approach is the use of cells with limited developmental potency, such as endodermal progenitor cells. However, ESC in a non-naïve state lack the patency to form chimera as they appear to undergo apoptosis in complemented blastocysts. 330, 331 The expression of Bcl-2 prevented apoptosis in Sox17+ and Nkx2.5+ progenitor cells after blastocyst complementation, enabling region specific, pancreatic chimera. 330, 331 Taken together, these developments open the tantalizing possibility to generate autologous, patient specific human pancreata in pigs that could be used for pancreas or islet transplantation. 332, 333 Successful decellularization of the pancreas 334 has fuelled the bioengineering of organs for transplantation, 335 where these scaffolds are reseeded with allogeneic or autologous PSC-derived β cells or donor derived islets to improve their engraftment and function. 334, [336] [337] [338] [339] The cellular microarchitecture of pancreatic islets, including vascularization and innervation, has even been constructed using 3D bioprinting of single cells. 340 
CONCLUSIONS
The next 10 years will see a continued dependence on pancreas and islet transplantation for selected high-risk patients with T1DM. However, rapid progress in the areas of xenogeneic islet transplantation, stem cell-derived β cells or other emerging β cell sources will ultimately replace the limited sources of adult human tissue. Although xenotransplants were previously thought to be compromised by both immune destruction and zoonotic infections, the success of porcine islets transplanted into diabetic NHPs 179, 180 and multiplex gene editing to reduce immunogenicity and infectious risk 131, 211, 341 may help overcome these barriers. Similarly, protocols to derive β-like cells from either embryonic and iPSC sources continue to improve in generating fully functional cells in vitro. 44, 45, 252, 342 The generation of fully differentiated β-like cells and other strategies may decrease the risk of neoplastic transformation after transplantation. Finally, the continued development of strategies to protect β cell grafts from recurrent autoimmunity and alloimmunity, 72, 211, 304, 343 as well as immunotherapy for T1DM, may assist in making β cell replacement therapy possible for all people with diabetes (Table 1) .
In the meantime, closed loop, mono, or bihormonal artificial pancreata are expected to further improve glycemic control and reduce the burden of diabetes management. 344 Several closed loop algorithms have been tested in clinical trials in both inpatient and at-home settings. A meta-analysis of these trials confirmed that study subjects had an increase in time spent in glucose target range and reduced HbA1c values, compared to open loop diabetes management and greater improvement with bihormonal systems. 344 However, although these artificial pancreata efficiently reduced glucose variability in the steady state, food intake and the multifactorial influences of daily activity on glycemia were not controlled to the extent a successful islet transplant provides. 142, [345] [346] [347] [348] [349] These shortcomings are expected, given that these artificial pancreas systems rely solely on the delayed measurement of glucose levels and are limited by the pharmacokinetics of exogenous insulin. 348 Considerable cost of this technology, including the ongoing expense of disposable supplies will likely limit access to this therapy. Nonetheless, we expect that artificial pancreata will fill the gap for low-risk T1DM patients until a safe and efficient β cell replacement is ready for prime time.
The upcoming decade will be an exciting time as we move forward with clinical trials using cutting edge technologies with the aim to provide a treatment for the millions of patients worldwide suffering from diabetes. Patients with diabetes are highly motivated to participate in clinical trials which offer the potential to relieve them of the burden of achieving tight control using exogenous insulin therapy. For that reason, it is the obligation of the medical and scientific community to assure scientific rigor and ultimate patient safety as we move forward with these novel strategies. 
